- Individuals diagnosed with pancreatic ductal adenocarcinoma aged 60 years and under regardless of other personal or family history factors.
- Individuals diagnosed with pancreatic ductal adenocarcinoma at any age with personal or family history suggestive of a familial cancer syndrome* or other phenotypic features suggestive of a known cancer syndrome.
- Individual from a population where a founder pathogenic variant of high prevalence exists (e.g. Ashkenazi Jewish).
- Individual diagnosed with pancreatic ductal adenocarcinoma and evidence of DNA mismatch repair (MMR) deficiency by immunohistochemical staining or microsatellite instability studies in the tumour tissue.
Genetic testing is important for good clinical care of individuals who are suspected of having a familial cancer/tumour predisposition.**
*Hereditary pancreatitis, Peutz-Jeghers syndrome, CDKN2A, BRCA1, BRCA2, Lynch syndrome
**Limited gene testing may be more appropriate in the setting of a specific phenotype